Myositis-associated autoantibodies (MAAs) or myositis-specific autoantibodies (MSAs) are detected in up to 80% of patients with IIM and are associated with specific clinical phenotypes [9, 10]. This evidence concerns the gene MAPKAPK5-AS1 and myositis disease.